Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Erratum: Full antagonism of the estrogen receptor without a prototypical ligand side chain.

Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I, Novick S, Nowak J, Cavett V, Zhou HB, Boonmuen N, Zhao Y, Min J, Frasor J, Katzenellenbogen BS, Griffin PR, Katzenellenbogen JA, Nettles KW.

Nat Chem Biol. 2017 May 17;13(6):691. doi: 10.1038/nchembio0617-691b. No abstract available.

PMID:
28514419
2.

Corrigendum: Full antagonism of the estrogen receptor without a prototypical ligand side chain.

Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I, Novick S, Nowak J, Cavett V, Zhou HB, Boonmuen N, Zhao Y, Min J, Frasor J, Katzenellenbogen BS, Griffin PR, Katzenellenbogen JA, Nettles KW.

Nat Chem Biol. 2017 May 17;13(6):691. doi: 10.1038/nchembio0617-691c. No abstract available.

PMID:
28514424
3.
4.

Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta.

Roelens F, Heldring N, Dhooge W, Bengtsson M, Comhaire F, Gustafsson JA, Treuter E, De Keukeleire D.

J Med Chem. 2006 Dec 14;49(25):7357-65.

PMID:
17149865
5.

1-Carbamoylalkyl-2-phenylindoles: relationship between side chain structure and estrogen antagonism.

von Angerer E, Biberger C, Holler E, Koop R, Leichtl S.

J Steroid Biochem Mol Biol. 1994 May;49(1):51-62.

PMID:
8003439
6.

Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.

Hardcastle IR, Rowlands MG, Grimshaw RM, Houghton J, Jarman M.

J Med Chem. 1996 Feb 16;39(4):999-1004.

PMID:
8632423
7.

Characterization of ligand type of estrogen receptor by MD simulation and mm-PBSA free energy analysis.

Liu JY, Mooney SD.

Int J Biochem Mol Biol. 2011;2(2):190-198. Epub 2011 Apr 23.

8.

A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment.

Liu J, Knappenberger KS, Kack H, Andersson G, Nilsson E, Dartsch C, Scott CW.

Mol Endocrinol. 2003 Mar;17(3):346-55. Epub 2002 Dec 5.

PMID:
12554768
9.

Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Liu H, Park WC, Bentrem DJ, McKian KP, Reyes Ade L, Loweth JA, Schafer JM, Zapf JW, Jordan VC.

J Biol Chem. 2002 Mar 15;277(11):9189-98. Epub 2001 Dec 20.

10.

Benzothiophene and naphthalene derived constrained SERMs.

Wallace OB, Bryant HU, Shetler PK, Adrian MD, Geiser AG.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5103-6.

PMID:
15380208
11.

Synthesis and estrogen receptor affinity of a 4-hydroxytamoxifen-labeled ligand for diagnostic imaging.

Lashley MR, Niedzinski EJ, Rogers JM, Denison MS, Nantz MH.

Bioorg Med Chem. 2002 Dec;10(12):4075-82.

PMID:
12413861
12.
13.

Antagonists selective for estrogen receptor alpha.

Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS.

Endocrinology. 2002 Mar;143(3):941-7.

PMID:
11861516
15.

The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors.

de Medina P, Boubekeur N, Balaguer P, Favre G, Silvente-Poirot S, Poirot M.

J Pharmacol Exp Ther. 2006 Oct;319(1):139-49. Epub 2006 Jul 11.

PMID:
16835370
16.

An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro.

Lieberman ME, Gorski J, Jordan VC.

J Biol Chem. 1983 Apr 25;258(8):4741-5.

17.

Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.

Jordan VC, Lieberman ME, Cormier E, Koch R, Bagley JR, Ruenitz PC.

Mol Pharmacol. 1984 Sep;26(2):272-8.

PMID:
6482874
18.
19.

Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.

Zheng Y, Zhu M, Srinivasan S, Nwachukwu JC, Cavett V, Min J, Carlson KE, Wang P, Dong C, Katzenellenbogen JA, Nettles KW, Zhou HB.

ChemMedChem. 2012 Jun;7(6):1094-100. doi: 10.1002/cmdc.201200048. Epub 2012 Apr 19.

20.

Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists.

Stauffer SR, Huang YR, Aron ZD, Coletta CJ, Sun J, Katzenellenbogen BS, Katzenellenbogen JA.

Bioorg Med Chem. 2001 Jan;9(1):151-61.

PMID:
11197335

Supplemental Content

Support Center